

Effective dose of granisetron for preventing postoperative emesis in children

Yoshitaka Fujii MD, Hidenori Toyooka MD,
Hiro Yoshi Tanaka MD*

Purpose: This study was to identify the minimum effective dose of granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, to prevent postoperative vomiting in children who have undergone strabismus repair, tonsillectomy or tonsillectomy with adenoidectomy.

Methods: In a randomized, double-blind fashion, 80 healthy children aged 4–10 yr were assigned to receive either placebo (saline) or granisetron in a dose of 20, 40 or 80 $\mu\text{g}\cdot\text{kg}^{-1}$ iv immediately following the induction of anaesthesia. All subjects received a standardized anaesthetic, which consisted of sevoflurane in nitrous oxide and oxygen. Rescue antiemetics were administered if two or more episodes of vomiting occurred. Postoperative pain was treated with acetaminophene pr or pentazocine iv. During the first 24 hr after anaesthesia, the frequencies of retching and vomiting were recorded in a standardized fashion by nursing staff while subjects were in a hospital.

Results: There were no differences among four treatment groups with regard to subject characteristics, surgical procedures, anaesthetic and postoperative management or adverse effects. The frequencies of these symptoms were as follows: 65%, 60%, 20% and 15% after administration of placebo, granisetron 20, 40 or 80 $\mu\text{g}\cdot\text{kg}^{-1}$. Three children who had received either placebo or granisetron 20 $\mu\text{g}\cdot\text{kg}^{-1}$ required

another rescue antiemetic drug, whereas none who had received granisetron 40 or 80 $\mu\text{g}\cdot\text{kg}^{-1}$ needed rescue drugs.

Conclusion: Granisetron 40 $\mu\text{g}\cdot\text{kg}^{-1}$ is an effective antiemetic for preventing retching and vomiting following strabismus repair and tonsillectomy in children. Increasing the dose to 80 $\mu\text{g}\cdot\text{kg}^{-1}$ provided no demonstrable benefit in reducing postoperative emesis.

Objectif: Cette étude visait à identifier la dose efficace minimale de granisetron, un antagoniste sélectif du récepteur de type 3 de la 5-hydroxytryptamine, nécessaire pour prévenir les vomissements postopératoires chez des enfants soumis à une correction de strabisme, ou à amygdaléctomie avec ou sans adénoïdectomie.

Méthodes: Au cours d'une étude aléatoire et en double aveugle, 80 patients âgés de quatre à dix ans ont été répartis pour recevoir soit une placebo, soit du granisetron à la dose de 20, 40 ou 80 $\mu\text{g}\cdot\text{kg}^{-1}$ iv immédiatement après l'induction de l'anesthésie. Tous les sujets ont reçu la même anesthésie soit du sévoflurane en oxygène et protoxyde d'azote. Un antiémétique de sauvetage était administré après deux épisodes de vomissements ou plus. La douleur postopératoire était traitée avec de l'acétaminophène rectal ou de la pentazocine iv. Pendant les 24 premières heures qui suivaient l'anesthésie, la fréquence des efforts pour vomir et les vomissements ont été enregistrés de façon standardisée par le personnel infirmier pendant le séjour des sujets à l'hôpital.

Résultats: Les caractéristiques, les interventions chirurgicales, la gestion anesthésique et postopératoire ou les réactions défavorables ont été les mêmes pour les deux groupes. La fréquence des vomissements a été de 65%, 60%, 20% et 15% respectivement après l'administration du placebo, du granisetron 20, 40 ou 80 $\mu\text{g}\cdot\text{kg}^{-1}$. Trois enfants qui avaient reçu le placebo ou le granisetron 20 $\mu\text{g}\cdot\text{kg}^{-1}$ ont eu besoin d'un antiémétique de sauvetage alors qu'aucun de ceux qui avaient reçu le granisetron 40 ou 80 $\mu\text{g}\cdot\text{kg}^{-1}$ n'a eu besoin d'un tel médicament.

Conclusion: Le granisetron 40 $\mu\text{g}\cdot\text{kg}^{-1}$ est un antiémétique efficace qui prévient les efforts pour vomir et les vomissements consécutifs à une correction de strabisme ou une amygdaléctomie chez l'enfant. L'augmentation de la dose à 80 $\mu\text{g}\cdot\text{kg}^{-1}$ ne procure pas d'avantages supplémentaires.

Key words

COMPLICATIONS: retching, vomiting;
VOMITING: antiemetics; granisetron;
SURGERY: paediatric; strabismus repair, tonsillectomy.

From the Department of Anaesthesiology and Critical Care Medicine, Tokyo Medical and Dental University School of Medicine, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113, Japan and the *Department of Anaesthesiology, Toride Kyodo General Hospital, 2-1-1, Hongo, Toride, Ibaraki 302, Japan.

Address correspondence to: Dr. Y. Fujii (Research fellow of the Critical Care and Respiratory Division), Royal Victoria Hospital, McGill University, 687 Pine Avenue West, Montreal, Quebec H3A1A1, Canada.

Phone: 03-3813-6111 (5325). Fax: 03-5803-0150.

Accepted for publication 23rd February, 1996.

Granisetron (Kytril®), a selective antagonist of the actions at 5-hydroxytryptamine type 3 (HT₃) receptor, has been shown to be effective in the clinical management of emesis associated with chemotherapy.¹ Recently, it has been demonstrated that granisetron reduces the frequency of postoperative emesis in children as well as in adults.^{2,3} However, the minimum effective dose of granisetron in paediatric subjects has not been reported. This study was performed to determine the minimum effective dosage of granisetron for preventing postoperative retching and vomiting in a randomized, double-blind comparison with placebo subjects undergoing general anaesthesia for strabismus repair and tonsillectomy in children.

Methods

Approval of the institutional ethics committee of Toride Kyodo General Hospital and informed consents from each parent were obtained. Eighty ASA physical status I or II paediatric subjects more than four years of age presenting for strabismus repair and tonsillectomy with or without adenoidectomy were eligible to participate. Within 24 hr before surgery, no child had experienced retching or vomiting and received any drug known to have antiemetic effect.

Solid food was not allowed after midnight and clear liquids were permitted up to three hours before surgery. The subjects were premedicated with bromazepam 3 mg *pr* one hour before operation. General anaesthesia was induced with sevoflurane in 66% nitrous oxide (N₂O) and oxygen (O₂) via mask, or thiopentone 5 mg · kg⁻¹ *iv*. Tracheal intubation was facilitated with vecuronium 0.1 mg · kg⁻¹ *iv*. After tracheal intubation, anaesthesia was maintained with N₂O/O₂ (2:1) and sevoflurane 0.5–3.0% (inspired concentration). Ventilation was controlled mechanically and was adjusted to keep PETCO₂ between 35 and 40 mmHg with an anaesthetic/respiratory gas analyzer (Capnomac Ultima, Datex, Finland). The subjects received, in a randomized, double-blind manner, a single *iv* dose of either placebo (saline) or granisetron (20, 40 and 80 µg · kg⁻¹) over two to five minutes after the induction of anaesthesia and prior to the surgical procedure. Neuromuscular blocking drugs were used as required. At the end of the surgical procedure, reversal of muscle relaxation was achieved with atropine sulphate 0.02 mg · kg⁻¹ *iv* and neostigmine 0.04 mg · kg⁻¹ *iv*, and then the trachea was extubated when the subject was awake. Rectal temperature was monitored and maintained 37 ± 1°C throughout surgery. Postoperatively, all subjects were admitted to the hospital. Clear liquids were offered only if the child requested, and other oral intake was not allowed for four hours after recovery from anaesthesia. If two or more episodes of vomiting

occurred within 24 hr after anaesthesia, standard antiemetic therapy (e.g., metoclopramide) was given. Postoperative analgesia was provided by acetaminophen 10–15 mg *pr* for mild to moderate pain and pentazocine 0.3 mg · kg⁻¹ *iv* for severe pain.

Postoperatively, all episodes of retching and vomiting during the 24 hr after anaesthesia were recorded by nursing staff who did not know which antiemetics the subjects had received. Retching was defined as the process of straining to expel the stomach contents without bringing out anything. Vomiting was defined as an act of expelling the stomach contents by an active process.⁴ Nausea was not assessed as a separate entity in this study because of the young age of the subjects. The details of any adverse effect throughout the study (0–24 hr after anaesthesia) were also recorded by a designated follow-up nurse who interviewed the parents of the subject.

Statistical analysis was performed with one-way analysis of variance (ANOVA) and Student's *t* test for continuous variables (subject demographic data). Discrete variables, such as the frequency and severity of postoperative retching and vomiting and the incidence of adverse effects, were compared with chi-square test. A *P* value of <0.05 was considered significant. All values expressed as mean ± SD.

Results

Subject demographics, surgical procedure, and anaesthetic and postoperative management are summarized in Table I. No difference existed among the four groups.

During the 24 hr after anaesthesia, the frequencies of postoperative retching and vomiting were 65%, 60%, 20% and 15% after administration of placebo, granisetron 20, 40 and 80 µg · kg⁻¹, respectively. Thus, the frequencies of these symptoms in subjects who had received granisetron 40 or 80 µg · kg⁻¹ were lower than those who had received placebo (*P* < 0.05). However, no differences in the frequency were observed between subjects who had received placebo and granisetron 20 µg · kg⁻¹. There were no differences in the frequency between subjects who had received granisetron 40 and 80 µg · kg⁻¹ (Table II).

Three children who had received either placebo or granisetron 20 µg · kg⁻¹ required another rescue antiemetic drug for two or more episodes of vomiting, whereas none who had received granisetron 40 or 80 µg · kg⁻¹ needed this agent (*P* < 0.05) (Table III).

No differences in the incidence of adverse effects were observed among the four groups (Table IV).

Discussion

This study was designed to determine the minimum

Table I Patient demographics and surgical procedures

| Group | Placebo (n = 20) | Granisetron | | |
|---|---------------------|---|---|---|
| | | 20 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 40 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 80 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) |
| Age (yr) | 6.7 \pm 2.3 | 6.5 \pm 2.2 | 6.5 \pm 2.1 | 6.5 \pm 2.2 |
| Height (cm) | 118.8 \pm 10.5 | 119.3 \pm 10.8 | 119.4 \pm 10.3 | 119.4 \pm 13.4 |
| Weight (kg) | 24.2 \pm 6.4 | 24.4 \pm 7.7 | 23.5 \pm 5.6 | 24.4 \pm 6.4 |
| Sex (male/female) | 11/9 | 12/8 | 12/8 | 11/9 |
| Induction of anaesthesia | | | | |
| – Sevoflurane, nitrous oxide and oxygen | 8 | 9 | 9 | 8 |
| – Thiopentone | 12 | 11 | 11 | 12 |
| Duration of operation (min) | 57.7 \pm 22.3 | 57.5 \pm 19.1 | 57.9 \pm 28.2 | 57.9 \pm 26.9 |
| Duration of anaesthesia (min) | 80.0 \pm 21.4 | 79.1 \pm 20.1 | 80.6 \pm 30.2 | 80.2 \pm 26.7 |
| Postoperative analgesic administered | | | | |
| – Acetaminophen (mg) | 245 \pm 60 | 240 \pm 75 | 250 \pm 61 | 245 \pm 69 |
| – Pentazocine (mg) | 1.5 \pm 3.1 | 1.6 \pm 3.3 | 1.6 \pm 3.2 | 1.5 \pm 3.1 |
| Types of operation performed | | | | |
| – Strabismus repair | 5 | 5 | 5 | 5 |
| – Tonsillectomy | 6 | 7 | 7 | 6 |
| – Tonsillectomy with adenoidectomy | 9 | 8 | 8 | 9 |

All values are expressed as mean \pm SD.

TABLE II Number (percentage) of patients experienced retching and vomiting during the 24 hr after anaesthesia

| Group | Placebo (n = 20) | Granisetron | | |
|---|---------------------|---|---|---|
| | | 20 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 40 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 80 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) |
| No. (%) of subjects experienced retching | 7 (35%) | 6 (30%) | 2 (10%) | 2 (10%) |
| No. (%) of subjects experienced vomiting | 6 (30%) | 6 (30%) | 2 (10%) | 1 (5%) |
| Total no. (%) of subjects experienced retching and vomiting | 13 (65%) | 12 (60%) | 4 (20%) | 3 (15%) |

TABLE III Severity of postoperative vomiting

| Group | Placebo (n = 20) | Granisetron | | |
|---------------------|---------------------|---|---|---|
| | | 20 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 40 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 80 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) |
| No. (%) of vomiting | | | | |
| – once | 3 (15%) | 3 (15%) | 2 (10%) | 1 (5%) |
| – twice or more | 3 (15%) | 3 (15%) | 0 (0%) | 0 (0%) |

TABLE IV Adverse effects

| Group | Placebo (n = 20) | Granisetron | | |
|---------------------|---------------------|---|---|---|
| | | 20 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 40 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) | 80 $\mu\text{g} \cdot \text{kg}^{-1}$ (n = 20) |
| Any adverse effects | 5 | 4 | 4 | 5 |
| – Headache | 2 | 2 | 2 | 2 |
| – Drowsiness | 2 | 2 | 2 | 2 |
| – Others | 1 | 0 | 0 | 1 |

effective dosage of granisetron for preventing postoperative retching and vomiting in paediatric subjects undergoing strabismus repair and tonsillectomy. The major findings were that during the 24 hr after anaesthesia, the frequency of postoperative emesis in subjects who had received granisetron 40 or 80 $\mu\text{g} \cdot \text{kg}^{-1}$ was lower than those in subjects who had received placebo or granisetron 20 $\mu\text{g} \cdot \text{kg}^{-1}$ ($P < 0.05$), but there was no differences in the frequency between subjects who had received granisetron 40 and 80 $\mu\text{g} \cdot \text{kg}^{-1}$.

The observed frequencies of retching and vomiting after strabismus repair and tonsillectomy performed

general anaesthesia in children are comparatively high.^{5,6} The cause of high incidence of postoperative emesis after these surgical procedure remains unclear, but it is probably multifactorial.⁷ A number of factors including age, sex, obesity, operative procedure, anaesthetic technique and postoperative pain are thought to increase the frequency of postoperative emesis. In this study, however, the treatment groups were similar for subject demographics, surgical procedure, anaesthetic administered and analgesics used postoperatively. Therefore, by eliminating these factors that might affect

postoperative emesis, the differences in the frequency of postoperative emesis among the groups can be attributed to the differences in dose of granisetron administered.

The results of this study, with an administration of granisetron $40 \mu\text{g} \cdot \text{kg}^{-1}$, showed that the effectiveness of this drug compared with placebo for preventing postoperative emesis. This was in agreement with our previous study.³

Granisetron has already been reported to be effective in the treatment of nausea and vomiting for preventing emesis induced by cancer chemotherapy.¹ It has also been reported recently that it is effective in reducing the frequency of these symptoms after surgery in children as well as in adults.^{2,3} Although the exact mechanism of granisetron in the prevention of postoperative emesis is not known, it has been suggested that it may act on sites containing 5-HT₃ receptors with demonstrated antiemetic effects.⁸

It has been shown that effective doses of granisetron are between 40 and $80 \mu\text{g} \cdot \text{kg}^{-1}$ for the treatment of cancer therapy-induced emesis.⁹ As previously demonstrated, granisetron $40 \mu\text{g} \cdot \text{kg}^{-1}$ is the optimal effective dose for preventing postoperative emesis in adults.¹⁰ This study demonstrated that granisetron $40 \mu\text{g} \cdot \text{kg}^{-1}$ was as effective as $80 \mu\text{g} \cdot \text{kg}^{-1}$, and that both resulted in reduction of the frequencies of postoperative emesis compared with granisetron $20 \mu\text{g} \cdot \text{kg}^{-1}$. Therefore, it is suggested that granisetron $40 \mu\text{g} \cdot \text{kg}^{-1}$ can be regarded as the minimum effective dose for preventing postoperative emesis in children as well as in adults.

This study also demonstrated that three subjects who had received either placebo or granisetron $20 \mu\text{g} \cdot \text{kg}^{-1}$ experienced a need for rescue drug, and that none who had received granisetron 40 or $80 \mu\text{g} \cdot \text{kg}^{-1}$ required rescue. This suggests that administration of either granisetron 40 or $80 \mu\text{g} \cdot \text{kg}^{-1}$ decreases the severity of postoperative emesis.

It has been reported that mild headache occurs in adult subjects received granisetron for preventing chemotherapy-induced nausea and vomiting.¹¹ However, no adverse events, including mental status to produce headache or drowsiness, considered to be related to this agent, were observed in this study. This was in accordance with our previous study for children.³ The exact reason for this difference is not known, but it may be attributed to the difference in age and relatively small number of subjects. Further studies are needed to verify the safety of granisetron before it can be routinely used to prevent postoperative emesis.

Several recent investigations of a new antiemetic drug, ondansetron, have been criticized because of its high cost.^{12,13} In Japan, the hospital pharmacy pays 10,020 yen for 3 mg (approximately $100 \mu\text{g} \cdot \text{kg}^{-1}$) of

granisetron. Thus, this drug as well as ondansetron is more expensive than other antiemetic drugs (e.g., 175 yen for droperidol 2.5 mg, 61 yen for metoclopramide). However, the use of droperidol and metoclopramide as antiemetics has been limited because these drugs may cause excessive sedation and extrapyramidal symptoms.^{14,15} Furthermore, on the basis of these results, the use of a lower dose, $40 \mu\text{g} \cdot \text{kg}^{-1}$, would decrease the cost of this drug.

In conclusion, this study suggests that granisetron $40 \mu\text{g} \cdot \text{kg}^{-1}$ is an effective antiemetic for preventing retching and vomiting following strabismus repair and tonsillectomy in children, and that increasing the dose to $80 \mu\text{g} \cdot \text{kg}^{-1}$ provided no demonstrable benefit in reducing postoperative emesis.

References

- 1 Bermudez J, Boyle EA, Miner WD, Sanger GJ. The antiemetic potential of the 5-HT_3 receptor antagonist BRL43694. *Br J Cancer* 1988; 58: 644–50.
- 2 Fujii Y, Tanaka H, Toyooka H. Reduction of postoperative nausea and vomiting with granisetron. *Can J Anaesth* 1994; 41: 291–4.
- 3 Fujii Y, Tanaka H, Toyooka H. Granisetron reduces vomiting after strabismus surgery and tonsillectomy in children. *Can J Anaesth* 1996; 43: 35–8.
- 4 Pandit UA, Malviya S, Lewis IH. Vomiting after outpatient tonsillectomy and adenoidectomy in children: the role of nitrous oxide. *Anesth Analg* 1995; 80: 230–3.
- 5 Abramowitz MD, Oh TH, Epstein BS, Ruttimann UE, Friendly DS. The antiemetic effect of droperidol following outpatient strabismus surgery in children. *Anesthesiology* 1983; 59: 579–83.
- 6 Carithers JS, Gebhart DE, Williams JA. Postoperative risks of pediatric tonsillectomy. *Laryngoscope* 1987; 97: 422–9.
- 7 Watcha M, White PF. Postoperative nausea and vomiting. Its etiology, treatment and prevention. *Anesthesiology* 1992; 77: 162–84.
- 8 Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694), a selective 5-HT₃ receptor antagonist: correlation with anti-emetic response. *Cancer Chemother Pharmacol* 1989; 24: 45–9.
- 9 Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. (I) Optimal dose-finding study (Japanese). *Journal of Clinical and Therapeutic Medicine* 1990; 6: 49–61.
- 10 Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. *Can J Anaesth* 1994; 41: 794–7.
- 11 Falkson G, van Zyl AJ. A phase I study of new 5HT₃-receptor antagonist, BRL43694A, an agent for the preven-

tion of chemotherapy-induced nausea and vomiting.
Cancer Chemother Pharmacol 1989; 24: 193–6.

- 12 *White PF, Watcha MF*. Are new drugs cost-effective for patients undergoing ambulatory surgery? (Editorial). *Anesthesiology* 1993; 78: 2–5.
- 13 *Lerman J*. Are antiemetics cost-effective for children? (Editorial). *Can J Anaesth* 1995; 42: 263–6.
- 14 *Dupre LJ, Stieglitz P*. Extrapyramidal syndromes after premedication with droperidol in children. *Br J Anaesth* 1980; 52: 831–3.
- 15 *Leung AKC, Lai PCW*. Use of metoclopramide for the treatment of gastroesophageal reflux in infants and children. *Current Therapeutic Research* 1984; 36: 911–5.

RETRACTED ARTICLE